Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Gain's clinical Parkinson's drug restores motor function in mice

Gain Therapeutics secures $10 million

Podcast – Reshaping Misfolding Enzymes - DEMENTIA RESEARCHER

Gain Therapeutics raised $46 million through Nasdaq listing

Gain Therapeutics Outlines SEE-Tx Platform and Computational

Why Is Gain Therapeutics (GANX) Stock Moving Today?

Roshan Ahmed on LinkedIn: Huge milestone for the Gain Therapeutics

What are the Strengths, Weaknesses, Opportunities and Threats of

GANX Price and Stats

INTEGRA Investor Outreach